By Michele Maatouk
Date: Wednesday 11 Dec 2019
LONDON (ShareCast) - (Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.
In a brief statement, the company noted the volatility in its share price following the recently-announced licensing and development agreement with US speciality pharmaceutical group Avion - which will see Avion will fund an international phase III trial for its lead programme, Lupuzor - and speculation about a possible fundraising.
"The board can confirm that the company is adequately funded and has no intention of raising funds," it said.
At 1510 GMT, the shares were up 1.5% at 18.02p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 2.14p |
Change Today | -0.020p |
% Change | -0.93 % |
52 Week High | 3.42 |
52 Week Low | 0.85 |
Volume | 1,367,460 |
Shares Issued | 416.44m |
Market Cap | £8.91m |
RiskGrade | 328 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:23 | 40,000 @ 2.17p |
16:11 | 88,630 @ 2.12p |
16:04 | 5,000 @ 2.11p |
15:51 | 5,233 @ 2.11p |
15:40 | 407 @ 2.19p |
You are here: research